Publications
194
Citations
6,565
Est. group size
—
Recurring co-author estimate
Active years
48
Publishing since 1979
Larry D. Cripe conducts clinical and translational research on blood cancers, especially acute myeloid leukemia (AML) and related conditions such as chronic myeloid leukemia, chronic lymphocytic leukemia, and myelodysplastic syndromes. The work spans clinical trials assessing treatment outcomes, molecular studies of cancer signaling pathways, and patient-centered topics like end-of-life care and helping patients define their goals.
Publication activity has fluctuated over the past decade, peaking around 2017-2018 and 2023, with a slower recent cadence averaging about five papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
No award with a current end date on record.
2 earlier awards
- NIH P30CA082709Sep 2004 – Aug 2008 · $82k awarded
Clinical Research Office
- NIH M01RR000750Dec 2005 – May 2008 · $0k awarded
SINGLE-CENTER PHASE I STUDY TO DETERMINE THE OPTIMAL BIOLOGIC DOSE OF CC-401
Matched to public NIH RePORTER and NSF records by name and institution. Awards from other agencies are not shown, and a match is not always found — this list may be incomplete.
Typically publishes in teams of ~13 · 12% small-team papers (≤3 authors) · across 30 venues
- FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML
npj Precision Oncology · 2026
- Elevated levels of TNF and its targets characterize better-risk older acute myeloid leukemia patients
Leukemia · 2026
- NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Journal of the National Comprehensive Cancer Network · 2026
- Comparative risk of major adverse cardiovascular events in polycythemia vera patients treated with ruxolitinib, hydroxyurea, or interferon: A real-world, propensity-matched cohort study
Blood · 2025
- Inferior survival in black AML patients treated with intensive chemotherapy in ECOG-ACRIN clinical trials is independent of cytogenetic profiles
Blood · 2025
- Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study
Blood · 2025
- Sparse whole genome sequencing and machine learning of AML genomes reveals novel, clinically relevant genetics.
Blood · 2025
- The Goal Inventory: An Innovative Digital Resource to Help Patients Identify and Evaluate Their Goals
Journal of Pain and Symptom Management · 2024
- Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials
Bone Marrow Transplantation · 2024
- Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials
Bone Marrow Transplantation · 2024
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024
Journal of the National Comprehensive Cancer Network · 2024
- POSTER: MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis
Clinical Lymphoma Myeloma & Leukemia · 2023
- P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS
HemaSphere · 2023
- Supplementary Figure 1 from A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
2023
- Supplementary Methods, Table 1, Figure Legend 1 from A Noncanonical Flt3ITD/NF-κB Signaling Pathway Represses DAPK1 in Acute Myeloid Leukemia
2023
- Blood×13
- Journal of Clinical Oncology×3
- Leukemia Research×3
- American Journal of Hospice and Palliative Medicine®×3
- Author eBooks×3
- Dale L. Bixby
Medicine · University of Michigan
- Annette S. Kim
Medicine · University of Michigan
- Allyson Waller
Medicine · The Ohio State University
- Yosra Ben Youssef
Medicine · The Ohio State University
- Bhavana Bhatnagar
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile